Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma

Abstract Background Metastatic renal cell carcinoma (RCC) patients are commonly treated with vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin inhibitors. Correlations between somatic mutations and first-line targeted therapy outcomes have not been reported on a r...

Full description

Saved in:
Bibliographic Details
Published in:European urology 2017-03, Vol.71 (3), p.405-414
Main Authors: Hsieh, James J, Chen, David, Wang, Patricia I, Marker, Mahtab, Redzematovic, Almedina, Chen, Ying-Bei, Selcuklu, S. Duygu, Weinhold, Nils, Bouvier, Nancy, Huberman, Kety H, Bhanot, Umesh, Chevinsky, Michael S, Patel, Parul, Pinciroli, Patrizia, Won, Helen H, You, Daoqi, Viale, Agnes, Lee, William, Hakimi, A. Ari, Berger, Michael F, Socci, Nicholas D, Cheng, Emily H, Knox, Jennifer, Voss, Martin H, Voi, Maurizio, Motzer, Robert J
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
BAP1
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - genetics
Carcinoma, Renal Cell - secondary
Disease-Free Survival
DNA-Binding Proteins
Everolimus
Everolimus - therapeutic use
Female
Genomic biomarker
Histone Demethylases - genetics
Histone-Lysine N-Methyltransferase - genetics
Humans
Indoles - therapeutic use
KDM5C
Kidney cancer
Kidney Neoplasms - drug therapy
Kidney Neoplasms - genetics
Kidney Neoplasms - pathology
Male
Middle Aged
Mutation
Nuclear Proteins - genetics
PBRM1
Prognosis
Proportional Hazards Models
PTEN Phosphohydrolase - genetics
Pyrroles - therapeutic use
Randomized Controlled Trials as Topic
SETD2
Sunitinib
Survival Rate
Targeted therapy
Transcription Factors - genetics
Tumor suppressor gene
Tumor Suppressor Proteins - genetics
Ubiquitin Thiolesterase - genetics
Urology
Von Hippel-Lindau Tumor Suppressor Protein - genetics
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Metastatic renal cell carcinoma (RCC) patients are commonly treated with vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin inhibitors. Correlations between somatic mutations and first-line targeted therapy outcomes have not been reported on a randomized trial. Objective To evaluate the relationship between tumor mutations and treatment outcomes in RECORD-3, a randomized trial comparing first-line everolimus (mTOR inhibitor) followed by sunitinib (VEGF inhibitor) at progression with the opposite sequence in 471 metastatic RCC patients. Design, setting, and participants Targeted sequencing of 341 cancer genes at ∼540× coverage was performed on available tumor samples from 258 patients; 220 with clear cell histology (ccRCC). Outcome measurements and statistical analysis Associations between somatic mutations and median first-line progression free survival (PFS1L) and overall survival were determined in metastatic ccRCC using Cox proportional hazards models and log-rank tests. Results and limitations Prevalent mutations (≥ 10%) were VHL (75%), PBRM1 (46%), SETD2 (30%), BAP1 (19%), KDM5C (15%), and PTEN (12%). With first-line everolimus, PBRM1 and BAP1 mutations were associated with longer (median [95% confidence interval {CI}] 12.8 [8.1, 18.4] vs 5.5 [3.1, 8.4] mo) and shorter (median [95% CI] 4.9 [2.9, 8.1] vs 10.5 [7.3, 12.9] mo) PFS1L, respectively. With first-line sunitinib, KDM5C mutations were associated with longer PFS1L (median [95% CI] of 20.6 [12.4, 27.3] vs 8.3 [7.8, 11.0] mo). Molecular subgroups of metastatic ccRCC based on PBRM1 , BAP1 , and KDM5C mutations could have predictive values for patients treated with VEGF or mTOR inhibitors. Most tumor DNA was obtained from primary nephrectomy samples (94%), which could impact correlation statistics. Conclusions PBRM1 , BAP1 , and KDM5C mutations impact outcomes of targeted therapies in metastatic ccRCC patients. Patient summary Large-scale genomic kidney cancer studies reported novel mutations and heterogeneous features among individual tumors, which could contribute to varied clinical outcomes. We demonstrated correlations between somatic mutations and treatment outcomes in clear cell renal cell carcinoma, supporting the value of genomic classification in prospective studies.
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2016.10.007